Ratings Yuhan Corporation

Equities

A000100

KR7000100008

End-of-day quote Korea S.E. Other stock markets 2024-09-12			5-day change	1st Jan Change
124,800.00 ^KRW	+3.83%		-10.60%	+81.40%

08-22	South Korean Shares Rise After BOK Rate Hold; Yuhan Gains on FDA Approval	MT
08-22	Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug for US Markets	MT

Highlights: Yuhan Corporation

Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses: Yuhan Corporation

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 60.04 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4361.97 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings Chart: Yuhan Corporation

Source: Surperformance

ESG chart: Yuhan Corporation

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
YUHAN CORPORATION		6.75B
MERCK KGAA		81.29B
KYOWA KIRIN CO. LTD.		12.01B
SK BIOPHARMACEUTICALS CO., LTD.		5.83B
BETTA PHARMACEUTICALS CO., LTD.		2.36B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.		1.93B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-	1.87B
SUPERNUS PHARMACEUTICALS, INC.	-	1.71B
CHANGCHUN BCHT BIOTECHNOLOGY CO.		1.34B
Average		12.79B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

B-

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes